Deus Tech 2.0 is a deeptech company dedicated to developing AI-powered applications that optimize operations in IVF clinics and laboratories. Our innovative solutions integrate both advanced time-lapse video analysis and genetic testing data to assess embryo viability with unparalleled accuracy. By combining these two approaches, we significantly reduce the time and cost associated with fertility treatments while improving overall patient outcomes.
Our flagship product is an AI/ML platform that provides fully automated embryo evaluation on day 5, advanced IVF analytics, and seamless connectivity with various time-lapse incubators and genetic testing systems. This integrated approach enables clinics to make more informed decisions, thereby increasing the success rate of embryo implantation.
Led by a team of experienced professionals in reproductive medicine and machine learning, we are committed to advancing the field of fertility technology and delivering innovative, reliable solutions to our partners and patients.
Company Details
- Employees
- 1
- Founded
- -
- Address
- Warsaw, Pl
- Industry
- Hospitals And Health Care
- NAICS
-
Health Care and Social AssistanceSocial Assistance
- Keywords
- Fertility, Femtech, Artificial intelligence, Machine learning, Healthcare, MedTech, Computer vision, Deep learning, AI, IVF, Medical Technology, Reproductive Medicine, Demography, FertilityTech, HealthTech, Innovation, Embryo Selection, Women, Future of Medicine, DigitalHealth.
- HQ
- Warsaw
Deus Tech 2.0 Questions
Deus Tech 2.0's LinkedIn profile is https://pl.linkedin.com/company/deus-tech-2-0
Deus Tech 2.0 has
1 employees.
View email and phone details for 1
employees at Deus Tech 2.0.
Deus Tech 2.0's industry is
Hospitals and Health Care
Deus Tech 2.0's top competitors are
Bta Finance Limited,
Research2guidance,
Eit Digital,
Everglow Vitality,
Left Lane Capital,
Hacking Hr,
Deus Tech,
Atlas Sgr,
Hexaware Technologies,
Deus Tech Services.
Deus Tech 2.0's categories are Hospitals and Health Care
Deus Tech 2.0's founding year is 2025
